| A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum (NCT06624670) | LEO Pharma | 2025-02-05 |
| A Study to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of LEO 158968 (NCT06444867) | LEO Pharma | 2025-01-07 |
| A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis (NCT06311682) | LEO Pharma | 2024-06-10 |
| A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares (NCT06013969) | LEO Pharma | 2023-10-22 |
| A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis (NCT05923099) | LEO Pharma | 2023-09-20 |
| A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema (NCT06004050) | LEO Pharma | 2023-09-05 |
| A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis (NCT05919082) | LEO Pharma | 2023-06-21 |
| Investigating the Safety of LEO 158968 in Healthy Volunteers (NCT05682352) | LEO Pharma | 2023-02-07 |
| Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis (NCT04305327) | LEO Pharma | 2022-12-07 |
| Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1) (NCT05388760) | LEO Pharma | 2022-09-07 |
| Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema (NCT05486117) | LEO Pharma | 2022-09-06 |
| Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema (NCT05355818) | LEO Pharma | 2022-07-14 |
| The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis (NCT05295732) | LEO Pharma | 2022-06-21 |
| A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema (NCT05259722) | LEO Pharma | 2022-06-15 |
| A Multi-omics Disease Signature Trial in Adult Patients With Moderate to Severe AD (NCT05470114) | LEO Pharma | 2022-05-19 |
| A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia (NCT05332366) | LEO Pharma | 2022-04-19 |
| Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA) (NCT05194540) | LEO Pharma | 2022-01-13 |
| A Trial to Evaluate Pharmacokinetics, Immunogenicity, Safety, and Tolerability of LEO 138559 in Healthy Japanese Subjects (NCT05099133) | LEO Pharma | 2021-11-03 |
| A Trial to Evaluate the Effect of Delgocitinib on the Heart Rhythm of Healthy People (NCT05050279) | LEO Pharma | 2021-09-29 |
| An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis. (NCT04922021) | LEO Pharma | 2021-07-14 |
| A Single and Multiple Ascending-dose Trial of LEO 153339 in Healthy Adults (NCT04883333) | LEO Pharma | 2021-05-17 |
| Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (NCT04871711) | LEO Pharma | 2021-05-10 |
| Clinical Trial to Evaluate UV-light-induced Allergic Skin Reactions After Application of Delgocitinib Cream (NCT04807751) | LEO Pharma | 2021-03-25 |
| Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab (NCT04533737) | LEO Pharma | 2020-12-17 |
| Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis (NCT04587453) | LEO Pharma | 2020-10-27 |
| Clinical Trial to Evaluate Light-induced Skin Reactions After Application of Delgocitinib Cream (NCT04361136) | LEO Pharma | 2020-04-23 |
| A Vehicle Controlled Study to Evaluate Safety and Efficacy of Topical TMB-001 for Treatment of Congenital Ichthyosis (NCT04154293) | LEO Pharma | 2019-12-03 |
| Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus. (NCT03958955) | LEO Pharma | 2019-07-09 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single and Multiple Doses of LEO 142397 in Healthy People, Including Japanese (NCT03995550) | LEO Pharma | 2019-07-03 |
| Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study (NCT03886246) | LEO Pharma | 2019-05-29 |
| Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children (NCT03826901) | LEO Pharma | 2019-02-20 |
| Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris (NCT03806790) | LEO Pharma | 2019-01-24 |
| A Trial to Investigate the Safety, Tolerability, and Drug Levels in Blood After Single and Multiple Doses of LEO 32731 in Healthy People (NCT03812198) | LEO Pharma | 2019-01-22 |
| Investigation of Flare and Remission in Subjects With Atopic Dermatitis (NCT03710044) | LEO Pharma | 2019-01-14 |
| Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis. (NCT03725722) | LEO Pharma | 2018-12-28 |
| Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7 (NCT03761537) | LEO Pharma | 2018-12-13 |
| Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema (NCT03683719) | LEO Pharma | 2018-11-28 |
| Tacrolimus Blood Levels After Topical Application of Tacrolimus on Healthy Skin (NCT03673527) | LEO Pharma | 2018-11-22 |
| A Study to Learn More About the Relationship Between the Development of a Gap in the Upper Lip (Cleft Lip) or in the Roof of the Mouth (Cleft Palate) in Newborns and the Use of Glucocorticoids by the Mother During Pregnancy: a Meta-analysis (NCT03788863) | LEO Pharma | 2018-11-16 |
| Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis (NCT03669757) | LEO Pharma | 2018-09-27 |
| Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4 (NCT03556592) | LEO Pharma | 2018-08-13 |
| Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betamethasone (Lianbang Beisong®) Cream and Fucicort® Lipid Cream Vehicle in Clinically Infected Atopic Dermatitis/Eczema (NCT03395132) | LEO Pharma | 2018-07-31 |
| Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5) (NCT03562377) | LEO Pharma | 2018-07-13 |
| Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6). (NCT03526861) | LEO Pharma | 2018-06-19 |
| Body PSOriasis: Long-term Relapse CONTROL (NCT03402828) | LEO Pharma | 2018-06-11 |
| Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis (NCT03514511) | LEO Pharma | 2018-05-07 |
| Dermatopharmacokinetic Trial of LEO 90100 Foam (NCT03476746) | LEO Pharma | 2018-03-20 |
| Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTEND (NCT03587805) | LEO Pharma | 2018-03-18 |
| Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (NCT03363854) | LEO Pharma | 2018-02-22 |
| Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects (NCT03442244) | LEO Pharma | 2018-01-30 |
| A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis (NCT03331835) | LEO Pharma | 2017-11-03 |
| Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata. (NCT03325296) | LEO Pharma | 2017-10-30 |